Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nobuaki Okamatsu"'
Publikováno v:
BMJ Open, Vol 14, Iss 3 (2024)
Objectives To investigate potential knowledge gaps between neurologists and non-specialists and identify challenges in the current management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), with a focus on ‘early diagnosis’ a
Externí odkaz:
https://doaj.org/article/18e1051d904540c79b5af96a0310e42e
Autor:
Hirokazu Kanegane, Masataka Ishimura, Toshinao Kawai, Satoshi Okada, Nobuaki Okamatsu, Madoka Go, Shinichi Noto
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionPrimary immunodeficiency diseases (PIDs) are rare inherited diseases resulting in impaired immunity. People with PID experience lower health-related quality of life (HR-QOL) and disease-related burdens in daily activities. This ongoing, p
Externí odkaz:
https://doaj.org/article/fdb5166eace947ac9f7107bad76bc11c
Autor:
Takako Negishi-Koga, Akiko Karakawa, Yuji Kiuchi, Nobuhiro Sakai, Masamichi Takami, Masahiro Chatani, Nobuaki Okamatsu
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::272e3fd06668db1eaf0880e2745dc502
https://doi.org/10.1254/jpssuppl.wcp2018.0_po1-4-38
https://doi.org/10.1254/jpssuppl.wcp2018.0_po1-4-38
Autor:
Erika Hayashi, Tomoyuki Yamakawa, Shuichi Kiyohara, Akiko Karakawa, Yuji Kiuchi, Nobuaki Okamatsu, Nobuhiro Sakai, Masamichi Takami, Koji Ishikawa, Takako Negishi-Koga, Katsunori Inagaki, Kazuaki Handa, Mayumi Tsuji, Masahiro Chatani
Publikováno v:
Bone. 138:115494
Extended osteoclast longevity is deeply involved in the pathogenesis of bone diseases such as osteoporosis and rheumatoid arthritis, though the mechanisms that determine osteoclast lifespan are not fully understood. Here we present findings indicatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae108486a9ef83ad8e7299d53c0b004
https://doi.org/10.1016/j.bone.2020.115494
https://doi.org/10.1016/j.bone.2020.115494
Autor:
Nobuaki Okamatsu, Katsuji Oguchi, Takako Negishi-Koga, Yurie Sato, Masamichi Takami, Akiko Karakawa, Yuji Kiuchi, Nobuhiro Sakai, Katsunori Inagaki, Naoka Kouyama
Publikováno v:
Biochemical and biophysical research communications. 491(3)
Denosumab, a fully human monoclonal antibody that neutralizes receptor activator of nuclear factor-κB ligand (RANKL) and blocks osteoclast differentiation, has received approval in Japan for use as an anti-resorptive drug for osteoporosis and skelet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2c45a8db8ba13fa9dc842de99d3ac01
https://pubmed.ncbi.nlm.nih.gov/28760341
https://pubmed.ncbi.nlm.nih.gov/28760341